Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies.

Yasuda SU, Zhang L, Huang SM.

Clin Pharmacol Ther. 2008 Sep;84(3):417-23. doi: 10.1038/clpt.2008.141. Epub 2008 Jul 9. Erratum in: Clin Pharmacol Ther. 2009 Dec;86(6):683.

PMID:
18615002
2.

Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999.

Evelyn B, Toigo T, Banks D, Pohl D, Gray K, Robins B, Ernat J.

J Natl Med Assoc. 2001 Dec;93(12 Suppl):18S-24S. Review.

3.

[Role of pharmacokinetic-pharmacodynamic relationships in drug development].

Bellissant E, Courcier-Duplantier S, Blin O; Giens XVII.

Therapie. 2002 Jul-Aug;57(4):347-57. French.

PMID:
12422555
5.

Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Dostalek M, Akhlaghi F, Puzanovova M.

Clin Pharmacokinet. 2012 Aug 1;51(8):481-99. doi: 10.2165/11631900-000000000-00000. Review.

PMID:
22668340
6.
7.

Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.

Dorne JL.

Fundam Clin Pharmacol. 2004 Dec;18(6):609-20. Review.

PMID:
15548231
8.

Sex differences in pharmacokinetics and pharmacodynamics.

Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF.

Annu Rev Pharmacol Toxicol. 2004;44:499-523. Review.

PMID:
14744256
9.

Developmental pharmacogenomics.

Neville KA, Becker ML, Goldman JL, Kearns GL.

Paediatr Anaesth. 2011 Mar;21(3):255-65. doi: 10.1111/j.1460-9592.2011.03533.x. Review.

PMID:
21320234
10.
11.

Pharmacogenomics and the future of toxicology testing.

Agrawal YP, Rennert H.

Clin Lab Med. 2012 Sep;32(3):509-23. doi: 10.1016/j.cll.2012.07.009. Review.

PMID:
22939305
12.

Neonatal clinical pharmacology.

Allegaert K, van de Velde M, van den Anker J.

Paediatr Anaesth. 2014 Jan;24(1):30-8. doi: 10.1111/pan.12176. Epub 2013 Apr 26. Review.

13.

An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.

Phan VH, Tan C, Rittau A, Xu H, McLachlan AJ, Clarke SJ.

Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1395-410. doi: 10.1517/17425255.2011.624513. Epub 2011 Sep 28. Review.

PMID:
21950349
14.

How pharmacogenomics (PG) are changing practice: implications for prescribers, their patients, and the healthcare system (PG series part I).

Preskorn SH, Hatt CR.

J Psychiatr Pract. 2013 Mar;19(2):142-9. doi: 10.1097/01.pra.0000428559.01953.73. Review.

PMID:
23507814
15.

[Research in the field of clinical pharmacology in the USSR].

Lakin KM, Makarov VA, Novikova NV.

Farmakol Toksikol. 1982 May-Jun;45(3):5-12. Russian.

PMID:
7047211
16.

Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.

Rostami-Hodjegan A.

Clin Pharmacol Ther. 2012 Jul;92(1):50-61. doi: 10.1038/clpt.2012.65. Epub 2012 May 30. Review.

PMID:
22644330
17.

Designing simple PK-PD studies in children.

Thomson AH, Elliott HL.

Paediatr Anaesth. 2011 Mar;21(3):190-6. doi: 10.1111/j.1460-9592.2010.03436.x. Epub 2010 Oct 29.

PMID:
21040154
18.

Symposium "Clinical Pharmacology Anno 2008". 10th Heymans Memorial Lecture.

Van Bortel L.

Verh K Acad Geneeskd Belg. 2009;71(6):315-34.

PMID:
20232787
19.

Integrated pharmacokinetics and pharmacodynamics in drug development.

Dingemanse J, Appel-Dingemanse S.

Clin Pharmacokinet. 2007;46(9):713-37. Review.

PMID:
17713971
20.

Regulatory agency consideration of pharmacogenomics.

Pendergast MK.

Exp Biol Med (Maywood). 2008 Dec;233(12):1498-503. doi: 10.3181/0806-S-207. Epub 2008 Oct 10. Review.

PMID:
18849547

Supplemental Content

Support Center